Source: Media Outreach
– Listing on the new “Sparks” segment of SIX Swiss Exchange for small and medium-sized companies is planned for Q1 2022, subject to market environment
– Xlife Sciences AG is a Swiss company focused on the value development and commercialization of promising research projects from universities and other research institutions in the field of life sciences
– The company is involved as incubator and accelerator in in 23 project companies until the successful exit after the proof-of-concept phase with the goal of participating in theirlong-term value development
– Xlife Sciences is currently listed on the Munich Stock Exchange and has a market capitalization of EUR 233 million as per end of 2021.
ZURICH, SWITZERLAND – EQS Newswire – 10 January 2022 – Xlife Sciences AG (XLS DE) confirms its intention to be listed on SIX Swiss Exchange, as communicated in November 2021. Subject to market environment, the listing on the new “Sparks” segment of SIX Swiss Exchange is still planned for Q1 2022.
Dr. Bernhard Scholz, Chairman of the Board of Xlife Sciences, comments: “Switzerland has a strong and dynamic life sciences industry and correspondingly knowledgeable investors and analysts. The new Sparks segment of the Swiss stock exchange is attractive for Xlife Sciences as an emerging growth company and should further increase our visibility and market transparency.”
Oliver R. Baumann, CEO of Xlife Sciences, added: “With the planned listing in Switzerland and the accompanying move to a regulated market, we aim to make our company more accessible to institutional investors, increase the liquidity of the stock and further enhance the transparency of Xlife Sciences.”
The CompanyXlife Sciences is a Swiss company focused on the value development and commercialization of promising research projects from universities and other research institutions in the field of life sciences. The goal is to bridge the gap from research and development to healthcare markets.
Xlife Sciences brings carefully selected early-stage projects in the four areas of technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage of development. The focus is on preclinical projects in biotechnology that are acquired with a successful spin-off by a university, a clinical center, or a research institution. Currently, eleven employees and eight consultants work for Xlife Sciences AG; across all project companies, there are more than 120 scientific employees, researchers, and project managers in total.
The team of Xlife Sciences has proven experience in the life sciences sector thanks to the many years of expertise in successful partnering of the company founders and the scientific advisory board. In addition to Chairman Dr. Bernhard Scholz, the Board of Directors comprises Christian Faber, Prof. Dr. habil. Michael B. Klein, Mark S. Müller, and Simon Schöni. The Management Team consists of CEO Oliver R. Baumann (also member of the Board of Directors), CFO Carl von Halem, Chief Scientific Officer (CSO) Frank Plöger, and Beat Kläui as Head of Accounting & Taxation.
The Value ChainXlife Sciences generally focuses its involvement in a project on the early phase, i.e., until completion of the so-called “proof-of-concept” phase, and subsequently strives to commercialize the project company, e.g., through a sale of the company or individual product candidates (“trade sale”), through out-licensing of products or patents, or through an IPO of the project company. This strategy enables Xlife Sciences to realize an increase in value already after the proof-of-concept phase. Potential future growth opportunities are also captured with possible milestone payments and royalties in the later market phase.
The Project CompaniesXlife Sciences cooperates with 15 prominent universities and research institutes from Germany and Switzerland, and reviews invention disclosures and project ideas in a thorough and structured three-step due-diligence process. If Xlife Sciences decides to take over the invention disclosure, usually a separate project company is founded for this purpose and prepared for the possible exit after a successful proof-of-concept phase (2-3 years). In addition, these companies are supported in positioning, structuring, and implementing their concepts, for example by providing management services. Furthermore, Xlife Sciences aims to create and exploit synergies between the project companies.
Currently, the portfolio of Xlife Sciences comprises 23 project companies. Five project companies are based in Switzerland, the others mostly in Germany. According to the current assessment of the Management Team, the project companies Veraxa Biotech, Laxxon Medical, Lysatpharma, Quadira Biosciences, Saniva, Vitruvia, Synimmune, Ix Therapeutics, and Baliopharm are among the short- and medium-term growth drivers of Xlife Sciences. These growth drivers can be, for example, an exit, the completion of the preclinical development phase, further commitments of federal funds or even the first-time revenue generation.
Planned listing on SIX Swiss ExchangeCurrently, the company is admitted to trading on the Munich Stock Exchange (unregulated market [“Freiverkehr”] in the segment m:access) with a market capitalization of EUR 233 million as of the end of 2021. Concurrently with the listing on SIX Swiss Exchange on the new “Sparks” segment, trading of the shares of Xlife Sciences AG on the Munich Stock Exchange shall be ceased for regulatory reasons. The shares will be tradeable on SIX Swiss Exchange after the switch to SIX Swiss Exchange.
Following the intended listing on SIX Swiss Exchange, the proportion of freely tradable shares (“free float”) is expected remain at approximately 44%, the current quota on the Munich Stock Exchange. The majority of the shares will continue to be held by the two founders as well as the members of the Board of Directors and management team.
Since October 1, 2021, fast-growing, small and medium-sized enterprises (SMEs) have been able to list on the “Sparks” segment of SIX Swiss Exchange. This is a regulated trading segment tailored to the requirements of SMEs and their investors. Among other things, the segment provides for easier access for younger companies and a condensed trading window. Apart from that, SMEs are subject to the same prospectus requirements, the same regulatory oversight and the same reporting requirements as companies traded on the main segment of SIX Swiss Exchange.
The issuer is solely responsible for the content of this announcement. – Published and distributed with permission of Media-Outreach.com.
